An interventional study of Atorvastatin 10 mg daily and Placebo matching atorvastatin in Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease and Vascular Cell Adhesion Molecule-1, sponsored by Suzhou Municipal Hospital of Anhui Province. Completed at 1 site in China. Open to participants aged 45 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-17.
Sponsored by Suzhou Municipal Hospital of Anhui Province · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.
Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 with no phase, and was the 40th registered.
128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.
Browse Cerebral Small Vessel Diseases studies →32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:
Dongzhimen Hospital, Beijing · Sites in China
Ages 50+
Peking Union Medical College Hospital · Sites in China
Ages 30–80
Beijing Tiantan Hospital · Sites in China
Ages 45–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 30–79
Beijing Tiantan Hospital · Sites in China
Ages 50–75 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 45 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 86 across 72 interventional studies indexed under Cerebral Small Vessel Diseases.
Median enrollment 105 across the 26 interventional studies, 749 across the 22 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 48 has an industry lead sponsor. The 10 most frequent:
Suzhou Municipal Hospital of Anhui Province is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Suzhou Municipal Hospital of Anhui Province has 1 study filed under Cerebral Small Vessel Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Cerebral Small Vessel Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06674460Phase 3Peking Union Medical College HospitalTreatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease | 2027-10-01 |
| NCT07317557Jiangsu Province Nanjing Brain HospitalRemote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease | 2026-12-31 |
| NCT07271732Dongzhimen Hospital, BeijingSongling Xuemaikang Capsules for Cerebral Small Vessel Disease | 2026-12-31 |
| NCT05356104Chinese University of Hong KongGLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) | 2027-05 |
| NCT06512376Beijing Tiantan HospitalHereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort | 2027-07-19 |
Add all 8 to your calendar (.ics) → With an account.
Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective study will enroll patients younger than 60 years with ischemic white matter lesions (WMIL) and age-matched healthy controls. We will measure circulating endothelial-related biomarkers, including endothelial progenitor cells (EPCs), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), asymmetric dimethylarginine (ADMA), and homocysteine (Hcy). We will also assess transcription levels of ICAM-1, VCAM-1, and ADMA. All participants will be followed and managed for 2 years, with repeated assessments of endothelial biomarkers and their transcriptional levels, as well as clinical and imaging evaluations. The aims are to characterize changes in endothelial biomarkers in WMIL, to determine how these changes relate to clinical features and imaging progression, and to evaluate whether statins protect endothelial function-by modifying these biomarkers-and thereby help treat WMIL and slow its progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with WMH receiving oral atorvastatin 10 mg once daily at 18:00 (6 p.m.) for 24 months. Standard assessments will be performed at baseline and follow-up.
Drug: Atorvastatin 10 mg daily
Participants with WMH receiving a placebo tablet matching atorvastatin, administered orally once daily at 18:00 (6 p.m.) for the same duration as the intervention arm. The same assessments will be performed.
Drug: Placebo matching atorvastatin
Health control participants with no study intervention; baseline and follow-up assessments only over the same schedule as patient groups.
Oral atorvastatin 10 mg administered once daily at 18:00 (6 p.m.) for 24 months. Dose form: tablet. Route: oral. Indicated for participants with WMH. Adherence monitored by pill count and diary. No dose titration planned.
Also known as: Atorvastatin calcium, ATV
Placebo tablet matching atorvastatin in appearance and packaging, containing inactive excipients only; taken orally once daily at 18:00 for 24 months.
VACM1 levels at 0.5, 1.0, 1.5, and 2.0 years
Time frame: 0.5, 1, 1.5, and 2.0 years after baseline
Ran from Jan 2021 to primary completion in Dec 2022, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Cerebral Small Vessel Diseases →
Suzhou Municipal Hospital of Anhui Province